相关实验视频
Updated: Jul 15, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
在1型糖尿病成年人中比较Control-IQ和开源AndroidAPS自动化胰岛素输送系统:CODIAC研究
Quoc Dat Do1, Aneta Hásková1, Lucie Radovnická2,3
13rd Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic.
Diabetes, obesity & metabolism
|September 25, 2023
概括
控制-智商 (CIQ) 系统在1型糖尿病管理方面显示了与AndroidAPS (AAPS) 相比的时间范围. 与AAPS相比,CIQ显著降低了低血糖事件,尽管用户没有计划切换系统.
科学领域:
- 内分泌学 在内分泌学.
- 生物医学工程 生物医学工程
- 糖尿病 技术 技术
背景情况:
- 自动注射胰岛素 (AID) 系统为1型糖尿病 (T1D) 提供先进的葡萄糖控制.
- 像AndroidAPS (AAPS) 这样的开源系统提供了可定制的解决方案,而像Control-IQ (CIQ) 这样的商业系统提供了集成的,用户友好的平台.
- 直接比较这些系统之间的切换对于理解现实世界的性能和用户偏好至关重要.
研究的目的:
- 为了前性地比较开源AndroidAPS (AAPS) 和商用Control-IQ (CIQ) 自动化胰岛素输送 (AID) 系统之间的切换的有效性和安全性.
- 评估关键的血糖控制指标,包括范围内的时间 (TIR),范围以上的时间 (TAR),范围以下的时间 (TBR) 和HbA1c.
- 评估用户的满意度和使用后继续使用系统的意图.
主要方法:
- 一个前性的,开放的,单臂临床试验,涉及25名T1D成年人.
- 参与者最初使用AAPS3个月,然后转换到CIQ3个月.
- 主要终点是70-80 mg/dL之间的时间变化范围 (TIR).
主要成果:
- 无论是AAPS还是CIQ都实现了可比的时间范围 (TIR) (84.24%±8.46%与85.72%±7.64%,P=0.12).
- 两种系统之间在超出范围的时间,传感器平均葡萄糖或HbA1c方面没有发现显著差异.
- 与AAPS (P<0.05) 相比,CIQ的时间低于范围 (低血糖症) 显着较低.
- 虽然用户对CIQ表示满意,但大多数人并不打算从AAPS转换.
结论:
- 科迪亚克研究提供了关于在AAPS和CIQ AID系统之间切换的第一个前性数据.
- 在TIR方面,CIQ和AAPS显示出可比的血糖控制.
- 与AAPS相比,CIQ通过减少低血糖症提供了显著的安全优势,尽管用户更喜欢AAPS.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
198
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
198
Insulin Formulations: Types and Delivery
218
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
218
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Diabetes: Management and Pharmacotherapy
302
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
302
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K

